1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Roche Introduces VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail Assay

21 Jun 2024
Admin
News Article

Roche Introduces VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail Assay

Roche introduces VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, a new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

Overview

Roche announced the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. The test is designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection.

B-cell lymphoma

B-cell lymphoma is a type of cancer that typically develops in the lymphatic system.
It accounts for approximately 85 per cent of non-Hodgkin lymphoma (NHL) cases.
NHL is the tenth most common cancer worldwide and each year more than 250,000 people die from this disease.
In the early stages of NHL, patients may experience symptoms like swelling of the lymph nodes, fever, fatigue, and loss of appetite or a red rash.

Words from CEO: Roche Diagnostics

“It’s important to be able to provide patients with a definitive diagnosis as symptoms of lymphoma can appear similar to the body’s normal reactive response to an infection,” said Matt Sause, CEO of Roche Diagnostics.
“This highly sensitive assay offers diagnostic certainty for patients with suspected B-cell lymphoma.”

About the New Test

With increased sensitivity, the new test enables assessment across the more than 60 B-cell lymphoma subtypes and plasma cell neoplasms on a single tissue slide.
The test can assess small biopsies and formalin-fixed tissue, reducing the need for a fresh tissue sample, which may not be available especially if lymphoma was not originally suspected.
These test properties preserve tissue, may result in fewer additional patient biopsies and make interpretation quicker and easier for the pathologist, helping create a faster diagnosis and access to treatment for patients.

First-of-its’s-kind Assay

This first-of-its-kind assay is a significant addition to Roche’s industry-leading hematopathology portfolio, which includes more than 65 biomarkers.

Dual ISH mRNA Probe Cocktail

VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail is intended for the qualitative detection of Kappa mRNA and Lambda mRNA in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue stained on a BenchMark IHC/ISH instrument using chromogenic in-situ hybridisation (ISH) and visualised using light microscopy.
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail is intended as an aid in the identification of B-cell lymphomas and plasma cell neoplasms.
The results of the assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.
This product is intended for in vitro diagnostic (IVD) use.